Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Q3 Losses Up as Expenses Rise

Premium

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.

Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.

Meanwhile, research and development costs climbed to $7.5 million from $2.4 million, reflecting the initiation of clinical testing of its Phase I cancer drug DCR-MYC and preparations to advance the preclinical primary hyperoxaluria 1 treatment DCR-PH1 into human trials.

General and administrative expenses rose to $3.7 million from $1.3 million, in part due to the costs associated with operating as a public company following Dicerna's initial public offering earlier this year.

At the end of the quarter, Dicerna had cash, cash equivalents, and held-to-maturity investments totaling $111.9 million.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.